ACON · XBRL financial data

Aclarion financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACON's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	19	14*	10	11	14	10*	19	19	19	18*	21	25
Cost of revenue	20	19*	19	23	21	21*	23	14	15	17*	17	17
Gross profit	(0)	(6)*	(9)	(12)	(7)	(10)*	(4)	5	4	2*	4	8
Research and development	198	221*	239	202	196	252*	198	270	302	263*	315	297
General and administrative	771	721*	846	696	860	1,206*	987	1,127	901	1,110*	1,766	1,734
Total operating expenses	1,162	1,121*	1,266	1,123	1,289	1,796*	1,487	1,742	1,835	1,995*	2,991	2,908
Operating income (loss)	(1,162)	(1,126)*	(1,275)	(1,136)	(1,296)	(1,806)*	(1,492)	(1,737)	(1,831)	(1,993)*	(2,987)	(2,900)
Interest expense	166	393*	336	—	—	year only	—	—	—	—	—	—
Other income (expense)	0	(1)*	93	(0)	0	(93)*	42	136	125	(307)*	0	(5)
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(998)	(1,265)*	(2,399)	(1,238)	(1,366)	(1,990)*	(2,037)	(1,601)	(1,706)	(1,889)*	(2,854)	(2,748)
Earnings per share, basic USD per share	(0.12)	—	(0.44)	(0.15)	(0.15)	—	(9.32)	(2.75)	(2.93)	—	(1.34)	(1.12)
Earnings per share, diluted USD per share	(0.12)	—	(0.44)	(0.15)	(0.15)	—	(9.32)	(2.75)	(2.93)	—	(1.34)	(1.12)
Weighted average shares, basic thousands of shares	8,527	—	5,443	8,217	9,438	—	219	582	582	—	2,130	2,462
Weighted average shares, diluted thousands of shares	8,527	—	5,443	8,217	9,438	—	219	582	582	—	2,130	2,462

† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ACON's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	171	1,021	2,133	1,173	1,312	454	14,750	12,826	11,341	12,016	19,005	16,285
Accounts receivable	21	13	17	20	17	18	19	21	32	30	41	28
Prepaid and other current assets	172	245	378	649	558	342	378	470	407	316	296	446
Total current assets	365	1,289	2,538	1,852	1,897	824	15,157	13,441	11,905	12,397	19,377	16,794
Property and equipment, net	2	2	1	1	1	5	5	6	13	24	23	23
Total assets	1,543	2,460	3,727	3,089	3,188	2,123	16,480	14,755	13,200	13,672	20,641	18,040
Accounts payable	686	761	196	179	332	532	516	282	274	333	587	705
Accrued liabilities	12	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	2,371	3,188	1,222	1,447	678	1,153	699	564	700	837	986	1,037
Total deposits	—	—	—	—	—	464	1,395	—	—	—	—	—
Total liabilities	—	3,188	1,222	1,447	678	1,153	699	564	700	837	986	1,037
Accumulated deficit	(43,016)	(44,282)	(46,681)	(47,919)	(49,273)	(51,262)	(53,300)	(54,901)	(56,607)	(58,496)	(61,350)	(64,097)
Total stockholders' equity	(828)	(728)	2,505	1,642	2,510	970	15,781	14,190	12,501	12,835	19,654	17,003
Total liabilities and equity	1,543	2,460	3,727	3,089	3,188	2,123	16,480	14,755	13,200	13,672	20,641	18,040
Common shares outstanding (cover page) thousands of shares	8,793	7,154	8,204	8,611	10,431	582	582	582	671	2,282	2,462	2,882

† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ACON's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(998)	(1,265)*	(2,399)	(1,238)	(1,366)	(1,990)*	(2,037)	(1,601)	(1,706)	(1,889)*	(2,854)	(2,748)
Stock-based compensation	137	100*	86	70	75	57*	56	28	17	4*	5	102
Depreciation and amortization	41*	42*	45	46*	50*	52*	55	53*	58*	61*	61	62*
Net cash from operating activities	(953)*	(734)*	(2,239)	(1,055)*	(1,056)*	(923)*	(2,511)	(1,866)*	(1,160)*	(1,627)*	(2,642)	(2,657)*
Purchases of property and equipment	—	year only	—	—	0*	5*	—	—	7*	14*	—	—
Net cash from investing activities	(13)*	(34)*	(64)	(94)*	(104)*	(61)*	(78)	(44)*	(40)*	(41)*	(49)	(43)*
Proceeds from issuing common stock	0*	0*	2,691	0*	0*	(2,691)*	5,168	0*	0*	535*	1,036	0*
Proceeds from issuing equity	—	—	—	—	—	year only	—	—	—	—	10,400	0*
Net cash from financing activities	522*	1,627*	3,414	188*	1,299*	125*	16,886	(0)*	(284)*	2,343*	9,680	(19)*

† Share count changed about 1/18 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aclarion	16,285	25	(2,657)*	2.9M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
BioNexus Gene Lab	1,233	76	(422)*	2.9M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Advanced Biomed	386	year only	(583)*	1.7M	0.7 quarters	Q4 FY26 10-KJun 30, 2026
Ludwig Enterprises	18	not reported	(153)	167.2M	1.3 quarters	Q1 FY26 10-QMar 31, 2026
CapForce	144	50,000	(618)*	12.4M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
American Shared Hospital Services	6,511	8,430	2,236*	6.7M	—	Q2 FY26 10-QJun 30, 2026
Biodesix	29,996	26,861	(1,562)*	10.6M	19.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.